Culture

Bioengineers learn the secrets to precisely turning on and off genes

image: Like the layers of a Russian doll, using multi-level regulation in an engineered cell ensures gene expression only switches on precisely when needed

Image: 
Thomas Gorochowski

In a recent study led by the University of Bristol, scientists have shown how to simultaneously harness multiple forms of regulation in living cells to strictly control gene expression and open new avenues for improved biotechnologies.

Engineered microbes are increasingly being used to enable the sustainable and clean production of chemicals, medicines and much more. To make this possible, bioengineers must control when specific sets of genes are turned on and off to allow for careful regulation of the biochemical processes involved.

Their findings are reported today in the journal Nature Communications.

Veronica Greco, lead author and a Royal Society funded PhD student at Bristol's School of Biological Sciences, said: "Although turning on or off a gene sounds simple, getting a living cell to do it on command is a real challenge. Every cell is slightly different, and the processes involved are not 100 percent reliable."

To solve this issue, the team took inspiration from nature where key events are often controlled by multiple processes simultaneously.

Veronica Greco added: "If you look at a Venus flytrap you find that a trap will only close when multiple hairs are triggered together. This helps reduce the chance of a trap closing by accident. We wanted to do something similar when controlling the expression of a gene inside a cell, adding multiple-levels of regulation to ensure it only comes on precisely when we want it to."

Professor Claire Grierson, co-author and Head of the School of Biological Sciences at Bristol, added: "What was wonderful about this project was how well it worked to harness two of the core processes present in every cell and underpinning all of life - transcription and translation."

The team showed that by using this type of multi-level regulation, they could create some of the most high-performance switches for gene expression built to date.

Moreover, working in collaboration with Dr Amir Pandi and Prof Tobias Erb from Bristol's Max Planck Institute for Terrestrial Microbiology, the team were able to go a step further. They demonstrated that even when used outside of living cells, these multi-level systems offered some of the most stringent control over gene expression yet seen.

Dr Thomas Gorochowski, senior author and a Royal Society University Research Fellow at Bristol, said: "When we engineer microbes, we often try to simplify our systems as much as possible, thinking we'll have better control over what is happening. But what we've shown is that embracing some of the inherent complexity of biology might be the key to fully unlocking its potential for the high-precision biotechnologies of tomorrow."

Credit: 
University of Bristol

More is better, when it comes to case volume for complex gastrointestinal cancer surgery

video: Outcomes of Complex Gastrointestinal Cancer Resection at US News & World Report Top-Ranked vs Non-ranked Hospitals

Image: 
American College of Surgeons

Key takeaways

Nearly half of gastrointestinal cancer operations in this study were performed at 42 U.S. News & World Report "Best Hospitals."

These top-ranked hospitals performed more than four times the annual case volume of unranked hospitals.

Higher hospital case volume was associated with better outcomes, even after accounting for patient characteristics and complicating factors.

Patients with complex gastrointestinal (GI) cancers may fare better by seeking surgical care at high-volume, top-ranked hospitals.

CHICAGO (March 19, 2021, 9 a.m. CDT): A new study reinforces the principle that "practice makes perfect" when it comes to complex GI cancer operations. Patients whose procedures for gastrointestinal malignancies were performed by a surgical team at a hospital ranked as one of America's "best" by U.S. News & World Report were nearly two and half times more likely to survive the operation than those who had the same procedure done at an unranked hospital. These new research findings are published online in advance of print on the website of the Journal of the American College of Surgeons.

Every year, U.S. News & World Report releases a list ranking the top 50 hospitals for specialty and overall care. These rankings, made available to the public, are based on measures in patient outcomes, patient experience, care-related factors, and expert opinion.

The annual issue plays a role in guiding patients and providers to high quality health care centers. Still, the reliability and accuracy of these rankings for high-risk gastrointestinal surgery is not known.

"Our study demonstrates the U.S. News & World Report ranking is a very appropriate resource," said study coauthor Ninh T. Nguyen, MD, FACS, chair, department of surgery, University of California, Irvine. "Now that we've actually done this analysis, we see the ranking does make sense when you look at surgical case volume and other related issues. Patients who seek surgical care at the top-ranked hospitals actually fare better, particularly if they are treated for the complex surgical conditions examined in this study."

Study details

Using data from the Vizient clinical database, the researchers assessed 6,662 patients who underwent elective esophagectomy, gastrectomy, or pancreatectomy for malignancies in 2018 at U.S. academic centers and their affiliated community hospitals. The study findings include the following:

Of the 6,662 gastrointestinal cancer operations performed, nearly half (3,054) were performed at 42 top-ranked hospitals, compared with 3,608 performed at 198 non-ranked hospitals.

The average annual case volume for these high-risk conditions was four times higher at top-ranked hospitals, compared with non-ranked hospitals (72 cases versus 18 cases).

Compared with non-ranked hospitals, top-ranked hospitals had a much lower in-hospital death rate. Specifically, that rate was almost 1 percent at top ranked hospitals compared with 2.26 percent at non-ranked.

Top ranked hospitals had a lower in-hospital mortality index compared to non-ranked hospitals (0.71 versus 1.53). A score of less than 1 means less patients died than expected based on their characteristics and preexisting comorbidities, and a score of more than 1 means more patients died than expected.

For patients who developed serious complications after their operations, top-ranked hospitals had a much lower in-hospital death rate compared with non-ranked hospitals (8.19 percent versus 16.79 percent).

"Anastomotic or pancreatic leaks are a serious postoperative complication that can be associated with an exceedingly high risk of death. Based on our study findings, surgical teams at top-ranked hospitals are likely better at detecting and managing these serious complications, and more likely to save patients from dying from the complication," Dr. Nguyen said. "For patients, that means if you had your operation performed at a non-ranked center, you are 2.35 times more likely to die than if you had it performed at a top-ranked hospital."

Benefits for high- and low-risk patients

After the researchers factored in patient characteristics such as severity of illness, the death rates were still, on average, lower in the high-volume, ranked hospitals versus non-ranked hospitals.

"When we think of top-ranked hospitals, we imagine these hospitals would perform better for patients who are higher risk, older, or have more comorbidities, but our analysis also examined outcomes based on severity of illness, and we found that even younger, low-risk patients fare better when they go to a top-ranked hospital," Dr. Nguyen said. "So even if you are healthy, and you're dealing with a complex GI condition requiring surgical resection, you are probably better off also obtaining care at a top-ranked hospital."

Accurate decision-making data empowers patients

"Deciding where to go for treatment is a collaborative decision that should be made between the patient and their physician. But one of the resources you can use is the annual U.S. News & World Report list," Dr. Nguyen said. "These are complex GI operations with a much higher risk of mortality. Therefore, you really want to go to a hospital where the surgical team performs a lot of these operations."

Credit: 
American College of Surgeons

New antibiotic clears multi-drug resistant gonorrhea in mice in single dose

image: A new antibiotic compound clears infection of multi-drug resistant gonorrhea in mice in a single oral dose, according to a new study. The compound, MBX-4132, binds to the bacterial ribosome and, in so doing, displaces a region of a protein (bL27, purple) that is critical to the trans-translation pathway in bacteria.

Image: 
Dunham Lab, Emory University

UNIVERSITY PARK, Pa. -- A new antibiotic compound clears infection of multi-drug resistant gonorrhea in mice in a single oral dose, according to a new study led by researchers at Penn State and Emory University. The compound targets a molecular pathway found in bacteria but not humans and could lead to new treatments for gonorrhea and infections from other bacteria, such as tuberculosis and MRSA.

The research team, which also includes scientists from the biopharmaceutical company Microbiotix, the Uniformed Services University, and Florida State, published their results in a paper appearing March 19 in the journal Nature Communications.

Gonorrhea infects more than 500 thousand people in the United States each year, and several strains of the bacteria that causes the disease, Neisseria gonorrhoeae, are resistant to multiple antibiotics in use today. For this reason, the Centers for Disease Control and Prevention (CDC) lists multi-drug resistant gonorrhea as one of the five most dangerous urgent threats today.

"Many current antibiotics target the process of translation--when proteins are made based on information in genetic material--within the bacteria," said Ken Keiler, professor of biochemistry and molecular biology at Penn State and an author of the paper. "Over the last decade, we have been investigating a family of compounds that instead inhibit the trans-translation pathway in bacteria, which bacteria use to fix certain kinds of errors during protein synthesis. In this paper, we provide a proof-of-concept that inhibiting the trans-translation pathway can effectively clear multi-drug resistant gonorrhea in animals."

The researchers previously identified a promising trans-translation inhibitor that clears gonorrhea infection in lab cultures but is ineffective in animals because the compound breaks down. In this study, members of the research team at Microbiotix strategically altered the compound to identify which portions of its structure were necessary to inhibit the pathway and which could be changed to improve its stability.

"Our iterative optimization campaign evaluated over 500 versions of the compound to assess their potency, toxicity, and other pharmacological properties," said Zachary Aron, director of chemistry at Microbiotix and an author of the paper. "We determined that the central region of the compound plays a critical role in blocking the trans-translation pathway, however modifications at the periphery could be altered to modulate its pharmacological properties. By altering a functional group to sidestep the primary mechanism of metabolism, we can create versions of the compound that are much more stable in animals."

Members of the research team at the Uniformed Services University then tested one of these modified compounds, MBX-4132, in mice. Their experiments utilized the gonorrhea strain WHO-X, an extremely virulent pathogen that is resistant to almost all approved antibiotics. A single oral dose of the compound completely cleared the infection in 80% of mice within six days, and the bacterial load in the remaining 20% was dramatically reduced.

"Developing a single dose therapy for gonorrhea is incredibly important," said Keiler. "In some cases, bacteria can develop resistance to a drug when additional doses are skipped, for example when a patient starts to feel better and stops taking antibiotics. With a single dose therapy, a patient could complete the treatment during a visit to their health provider."

To better determine how the compound inhibits the trans-translation pathway, members of the research team at Emory University and Florida State University used cryo-electron microscopy (cryo-EM) to produce high-resolution images of the compound as it binds to the bacterial ribosome--the macromolecule where proteins are synthesized.

"A derivative of MBX-4132 binds to a location on the ribosome that is different from all known antibiotic binding sites," said Christine Dunham, associate professor of biochemistry at Emory University and an author of the paper. "The new drug also displaces a region of a ribosomal protein that we think could be important during the normal process of trans-translation. Because trans-translation only occurs in bacteria and not in humans, we hope that the likelihood of the compound affecting protein synthesis in humans is greatly reduced, a hypothesis strongly supported by the safety and selectivity studies performed by Microbiotix."

The research team plans to further optimize the compound before pursuing preclinical trials.

"This type of compound is actually a broad-spectrum inhibitor," said Keiler. "It is effective against most Gram-positive bacteria--including tuberculosis and difficult-to-treat staph infections (MRSA)--and some Gram-negative bacteria and could be a promising candidate for future treatments. In this study, we lay the groundwork for using this type of compound and demonstrate that inhibiting the trans-translation pathway in bacteria is a viable antibiotic strategy."

Credit: 
Penn State

Three-dimensional imaging provides valuable insight to immune responses

image: By imaging intact lymphoid organs in three dimensions, researchers have been able to identify specialised niches, which can determine how immune T cells function.

Image: 
WEHI

A new imaging technique is shining a light on immune responses and setting the scene for enhancing immune memory to optimise vaccine strategies.

By imaging intact lymphoid organs in three dimensions, researchers have been able to identify specialised niches, which can determine how immune T cells function.

The research, published in Nature Immunology, is a step forward in understanding the differentiation of T cells - critical cells for developing strong immune responses - and how we can use these crucial findings to inform and optimise vaccine strategies.

At a glance

Three-dimensional imaging has enabled researchers to identify the factors that play a role in determining where immune memory cells locate to in the lymph node, in response to infection or cancer.

The research identified avenues to therapeutically target effector and memory cells for a host of applications, including vaccine development.

The findings will help inform and optimise future vaccination strategies.

Keeping memory cells at the ready

WEHI researchers Ms Brigette Duckworth and Dr Joanna Groom said the imaging technique could be applied to many different settings.

"By using this type of three-dimensional imaging, we have the power to visualise how and where immune cells decide their fate. There is real interest in understanding these mechanisms, as that gives us clues about how we can therapeutically target them and harness them for a host of applications, including vaccine development," Ms Duckworth said.

The team studied two types of immune cell: effector cells, which fight infections, and memory cells, which 'remember' how to fight specific infections, like viruses, so they can be rapidly cleared if they return in the future.

"These memory cells are particularly important because they keep chronic infections and cancers in check and act rapidly if we see the virus a second time," Ms Duckworth said.

"This work opens the door to harnessing extrinsic factors like vaccines to alter immune cell positioning in the lymph node and potentially direct the exact type of immune response we would like to generate."

Understanding vaccine strategies

Dr Groom said COVID-19 had put vaccines and vaccination strategies in the spotlight and had highlighted the importance of having a better understanding of our immune response to vaccination.

"These memory cells are what we want to generate when we vaccinate. Previously, we have focussed on the overall immune response, but our data suggests that may not be the best strategy," she said.

"A more efficient response might be to specifically direct vaccines towards memory formation because we want those cells to remain long after vaccination and to react when we come in contact with a virus."

Using T cell differentiation to improve the immune response

Dr Groom said the research team had identified factors that played a role in determining where the memory cells locate to in the lymph node.

"We have identified several ways we can modify the direction of the T cell differentiation," she said.

"These modifiers can be used as a lever to control whether we want more effector cells, which is good to overcome an immediate threat, such as cancer; or whether we want to switch to memory cells for longer lasting immunity benefits."

"We are now looking at these targets to identify the therapeutic window of opportunity and pinpointing which cells will be most effective and have the most impact in future vaccination strategies."

Credit: 
Walter and Eliza Hall Institute

Scientists identify genetic pathway that suppresses Lou Gehrig's Disease

image: Professor Chunghun Lim and his research team in the Department of Biological Sciences unveiled a neuroprotective pathway that suppresses Lou Gehrig's Disease (ALS).

Image: 
UNIST

Professor Chunghun Lim and his research team in the Department of Biological Sciences unveiled a neuroprotective pathway that suppresses Lou Gehrig's Disease (ALS).

Nucleocytoplasmic transport (NCT) defects have been implicated in neurodegenerative diseases, such as C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). In this study, the research team has identified a neuroprotective pathway of like-Sm protein 12 (LSM12) and exchange protein directly activated by cyclic AMP 1 (EPAC1) that sustains the nucleocytoplasmic RAN gradient and thereby suppresses NCT dysfunction by the C9ORF72-derived poly (glycine-arginine) protein.

The research team found that the LSM12-EPAC1 pathway is an important suppressor of the NCT-related pathologies in C9-ALS/FTD. The EPAC1 protein, which was expressed in this genetic pathway, normalizes the abnormal RAN gradient that determines the transport direction between the cell nucleus and the cytoplasm, thereby restoring its cellular function.

In general, the RAN proteins are more abundant in the cell nucleus, but in patients with Lou Gehrig's disease, they begin to leak out into the cytoplasm, thereby resulting in abnormal concentration differences. Their findings revealed that the EPAC1 protein, which was expressed through the LSM12-EPAC1 pathway, indeed helped EPAC1 return to the cell nucleus, thereby restoring the RAN gradient.

The research team also identified that the EPAC1 protein, which was expressed through the LSM12-EPAC1 pathway, regulates the distribution of RAN proteins. The EPAC1 protein increases the binding force between the nuclear pore complex (NPC) and the RAN proteins. Because of this, RAN proteins lost within the cytoplasm are, then, captured by the NPC and returned to the nucleus.

"Although the distribution of RAN proteins is critical for the nucleocytoplasmic transport (NTC), its molecular biological mechanism has relatively been unknown," says Professor Lim. "In this study, we have identified that LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient."

He adds, "Our findings are expected to contribute greatly to the prediction and treatment of neurodegenerative diseases, such as frontotemporal dementia and Lou Gehrig's disease, as well as for the understanding of the molecular mechanisms underlying aging."

Credit: 
Ulsan National Institute of Science and Technology(UNIST)

Hidden genetic defects contain real risks for serious diseases

For the first time researchers from Hebrew University of Jerusalem, Radboudumc, Maastricht UMC+ and international colleagues have gained insight into the "hidden genetic defects" of the general European population. This is important because these defects, if inherited from both father and mother, can lead to all kinds of illnesses in their children. Research in the Dutch and Estonian population shows that every person has two to four such hidden genetic defects. In 1 in 100 couples, this leads to a situation with an increased risk of a genetic disease for future children. In the case of consanguinity, even 20 percent of the couples appear to be at high risk. This research is published in The American Journal of Human Genetics and Genetics in Medicine.

The genes of a every person are half maternal, half paternal. Therefor you have two copies of each gene. Sometimes one of those two copies is defective, without making you sick because the other gene still functions properly. In this case we call it a 'hidden genetic defect' (in scientific terms: an autosomal recessive gene). Such a hidden genetic defect can cause problems if a child inherits the same hidden defect, the same mutated gene, from both father and mother. Both parents are healthy and have never suffered from the hidden genetic defect. But when these two hidden genetic defects (maternal en paternal) come together in the child, the disease manifests itself.

Hidden defects in sight

How often such hidden genetic defects occur in the general population has been unclear. By screening all the genes of nearly 6,500 people in the Dutch and Estonian population researchers from Radboudumc and Maastricht UMC+ have now obtained insight into how often such hidden defects that can lead to disease are present in a single individual. Christian Gilissen, researcher at Radboudumc: "Every human being appears to have on average 2 to 4 such hidden genetic defects. Therefore the chance that a European couple is at risk of having a sick child due to two such defects is about 1 percent. The risk increases sharply in consanguineous couples. In a relationship of cousins, about sixteen percent of the couples are at high risk, with a particularly increased risks for skeletal disorders or intellectual disabilities."

Higher risk with consanguinity

In addition to this research, published in The American Journal of Human Genetics, research was also conducted in the hospital's clinical practice coordinated by Maastricht UMC+, together with Radboudumc and Amsterdam UMC. This study, published in Genetics in Medicine, addresses the question of risk determination of hidden genetic defects in cousin relationships prior to a desired pregnancy. Clinical Molecular Geneticist Aimee Paulussen of Maastricht UMC+: "We mapped the risk in 100 consanguineous couples. About 20 percent of these couples were found to have an increased risk of serious disorders in their offspring through these hidden genetic defects. These results from clinical practice confirm the data already found in the population study mentioned above."

Valuable testing

Professor Han Brunner, head of the Department of Clinical Genetics Maastricht as well as the Department of Genetics Nijmegen, is involved in both studies. He sees them as a clear incentive to make genetic testing available to couples with a possible increased risk because of such hidden genetic defects: "Certainly for these couples, this information can help them to make an informed decision when starting a family. They can consider pre-implantation diagnostics and IVF to allow selection of embryos without these defects."

Credit: 
Radboud University Medical Center

New discoveries on deadly fungus - might be a key for treatment

image: Aspergillus fumigatus growing on a petri dish.

Image: 
Jan-Peter Kasper, University of Jena

Aspergillus fumigatus kills as many people as malaria and tuberculosis, but is less known. It is found "everywhere", for example in the soil or in our compost, but is not normally dangerous to healthy people.

Those who die from it often have a poor immune system or are hospitalized for lung infections, such as covid-19.

Aspergillus also constitutes an increasing problem in agriculture, because the fungus causes deadly infections in both plants and animals. In the same way that many bacteria are resistant to antibiotics, also this fungus is now becoming more and more resistant to the limited repertoire of treatments. It is therefore important to find new ways to fight fungal infections.

Researchers at the Department of Biomedicine at the Faculty of Medicine, UiB, together with researchers at the Faculty of Mathematics and Natural Sciences and a German research team, have now discovered an enzyme on the surface of the fungus.

The newly discovered enzyme breaks down a vital molecule that is important for the cells' energy metabolism: the NAD molecule, which is formed in our body from vitamin B3.

Without NAD, cells cannot survive. Therefore, the breakdown of NAD could affect immune cells and weaken our immune system to fight the fungal infection.

Recollected old scientific observations

Similar enzymes are found in bacteria that cause infections such as tuberculosis, streptococci or cholera. The idea that also fungi may have an NAD-degrading enzyme on their surface has been raised already in the 1950's:

"Enzyme activity that degrades NAD had been detected on the surface of a fungus, only the identity of the enzyme was never established. However, that fungus is commonly used in research laboratories and not known to be pathogenic. Probably, this discovery therefore went into the archive", says Professor Mathias Ziegler, leader of the study.

They want to re-examine the hypothesis that an enzyme, which breaks down NAD, may contribute to pathogenic mechanisms in fungi such as Aspergillus fumigatus.

"We measured strong enzyme activity on the surface of spores from Aspergillus fumigatus. It surprised us", says researcher and first author Øyvind Strømland.

Modern technology makes it possible to study the enzyme

"Using an elegant biochemical method, we identified fragments of the protein sequence from this enzyme. Since the entire genome of the fungus is known, we could then use these fragments to identify the gene that encodes the enzyme", says Ziegler.

"The next step was to use the genetic information and create a version of this gene that can be used by laboratory cell lines "trained" to produce sufficient amounts of the protein for detailed molecular studies", he continues.

In this way, researchers have been able to study how the enzyme breaks down NAD.

"There are two things that are central here. Highly sensitive analytical technology enabled identification of enzyme fragments. The other important element is that we now have the genome sequence and could easily identify the gene. That was not possible in the 50s", says Ziegler.

May design new drugs against the fungus

The researchers are clear that even though it is known from other diseases that similar bacterial enzymes break down NAD in infected cells, it cannot be said for sure that this is the case with the enzyme from Aspergillus fumigatus.

However, they know a lot more about the enzyme now through their research, and the hope is that the knowledge can help to discover new treatments for fungal infections.

Intriguingly, their bioinformatics analyses revealed that this type of enzyme is predominantly present in pathogenic fungi.

"If we could make a drug with molecules that resemble NAD, they might block the enzyme in our cells", the researchers suggest.

Credit: 
The University of Bergen

Vape aerosol and gene expression in human lung tissue compared to cigarette sm

image: The lungs are a key focus of research in vaping research studies.

Image: 
Imperial Brands

March 19, 2021, Bristol, UK - A new peer-reviewed study published in the journal Toxicological Research & Application shows acute exposure of a 3D human bronchial tissue model to e-cigarette aerosol has minimal impact on gene expression compared to smoke from combustible cigarettes.

The research involved sub-cytotoxic exposure to cells in a 3D human bronchial model (MucilAirTM) to nicotine-containing vape aerosol, combustible cigarette smoke and fresh air control under strict laboratory conditions.

The highly sensitive Toxicity Testing in the Twenty-First Century (TT21C)-based technique allows researchers to gain a mechanistic understanding of the potential effects of exposure to vape aerosol and 3R4F (reference cigarette) smoke, without experiencing other processes that may be triggered by significantly higher exposures - including cell death - that could potentially make interpretation of results difficult.

After cell 'recovery' periods of 4 and 48 hours, scientists assessed the expression of a variety of genes to determine if any were increased or decreased by the single exposure.

"Within this model, exposure to combustible cigarette smoke triggered significant changes in gene expression, indicating - amongst other effects - changes in oxidative stress and inflammation markers," confirmed Matt Stevenson, Pre-Clinical Toxicology Manager at Imperial Brands. "Conversely, the vape aerosol generated only a minimal response, similar to that observed in the air control."

Principal Toxicologist at Imperial Dr Liam Simms added: "Gene set enrichment analysis examining those genes most over/under expressed were compared across five key pathways - cell cycle, apoptosis, p53 signaling, cell death and NF-KappaB signaling [a protein complex that controls transcription of DNA, cytokine production and cell survival].

Focusing on the 3R4F reference cigarette, no pathways were activated after four hours exposure, but at 48 hours the cells had both genes associated with cell cycle and cell death pathways activated. Conversely, those cells exposed to vape aerosol demonstrated slightly elevated NF-KappaB signaling pathways after four hours exposure. However, at 48 hours no pathways were activated."

The results from this study show, that under the conditions of test, acute exposure to vape aerosol had less impact on gene expression in human lung cells in vitro than the equivalent dose of cigarette smoke.

"This latest research adds to the growing body of research gathered by both Imperial Brands and others, demonstrating the considerable harm reduction potential of Next Generation Products (NGPs) like vapes compared to continued combustible cigarette smoking," said Dr Grant O'Connell, Head of Tobacco Harm Reduction Science at Imperial.

"We encourage regulators and policy makers to consider the weight of evidence that shows the clear scientific differences between combustible cigarettes, which burn tobacco, and potentially harm-reduced NGPs that do not," he concluded.

Credit: 
Imperial Brands

Foreign-born run greater risk of workplace bullying

image: Michael Rosander, associate professor in psychology at Linköping University in Sweden

Image: 
Stefan Blomberg

The risk of being bullied at work is twice as high if you were born abroad. And if you come from a culture that is culturally dissimilar to Sweden's, the risk is even higher. These are the results of a Swedish study from Linköping University that was recently published in The International Journal of Human Resource Management.

Employers in Sweden have a duty to ensure that the workplace is safe, with a healthy atmosphere. Despite this, some employees are treated poorly, excluded and ignored. When such treatment has continued for a longer period, it is defined as bullying.

Researchers at Linköping University wanted to see if people born abroad run a greater risk of being bullied at work.

"Our results show an increased risk of bullying for people who work in Sweden but were born in another country. The results also show the importance of addressing these issues. Bullying can cause serious problems for a person, and for the workplace where it occurs", says Michael Rosander, associate professor in psychology at Linköping University's Department of Behavioural Sciences and Learning.

Michael Rosander's research investigates what happens at different types of workplaces and how different organisational factors affect individuals, working groups and the organisation as a whole. He conducted the study together with Stefan Blomberg, doctoral student at Linköping University.

Excluded from the work community

In this study, the researchers investigated two types of bullying: work-related and person-related bullying. In work-related bullying, one is subjected to negative actions related to one's work, for example having responsibilities taken away, being given trivial work duties, or having one's work monitored excessively.

Person-related bullying, on the other hand, is being subjected to negative actions related to one's person. It can include being humiliated, ridiculed, or ignored and excluded from social contexts.

The results show that people who are born abroad are subjected to more person-related bullying than people born in Sweden. For foreign-born, the risk of being bullied at work is twice as high as for natives. And for people from cultures dissimilar to the Swedish, the risk is quadrupled. Most exposed are people born in Asia.

However, for work-related bullying the researchers found no increased risk for foreign-born, compared to Swedish-born.

Thus, the person-related bullying that foreign-born are subjected to is based on who they are - not on work-related factors.

"They are subjected to what we call predatory bullying. It doesn't matter what they do. Their very presence, the way they look, can be a reason for the negative treatment. It became clear in the study, says Michael Rosander.

To measure the experience of being bullied, the researchers used the Swedish version of the Negative Acts Questionnaire-Revised (NAQ-R), where the respondents estimate their exposure to bullying at work in various situations on a five-point scale. Using register data from Statistics Sweden, the researchers sent the questionnaire to a representative selection of the Swedish workforce. The questionnaire was completed by 1856 people from workplaces of 10 people or more. The majority of respondents (1625) were born in Sweden, while 229 were born abroad.

Because it was already known that poor working conditions can be a breeding ground for bullying, the researchers also looked at certain work-related factors, in order to ensure that the responses concerned bullying specifically, and were not just general workplace dissatisfaction. But the analysis showed that these people don't have worse work environments - they are at a greater risk of being bullied.

Credit: 
Linköping University

The eukaryotic cell nucleus resembles the layout of a superstore

image: Shelves standing in the superstore are separated with aisles, so people can easily cross each aisle when doing shopping. The nucleus works like the superstore, where instead of shelves, there are chromatin fibers. These fibers have some channels, so molecules can move through them. Source: IPC PAS, photo: Grzegorz Krzyzewski

Image: 
Source: IPC PAS, Grzegorz Krzyzewski

The headquarter of a eukaryotic cell is the nucleus, and most of the cell's information and instructions are stored there in the form of DNA (Deoxyribonucleic acid). The DNA, which is twisted, rolled and bundled two-meter-long chain, together with protein molecules, makes up the chromatin fiber that lays inside the nucleus. For years, scientists were curious how these components are organized. How is it possible that proteins necessary in biochemical reactions move efficiently within the nucleus full of DNA? Recent studies have finally solved the mystery. Findings describing it in detail were published in the Journal of Physical Chemistry Letters on December 21st, 2020.

Molecules in a crowded nucleus

The nucleus of each cell hides a two-meter-long chain of a most amazing and unique molecule: DNA. Along with histones and various related proteins, DNA builds up a chromatin framework filled with a viscous fluid that exhibits excellent molecular composition diversity. For decades, the mobility of molecules in the nucleus was not sufficiently explored, but recent developments have altered this status quo. Thanks to in-depth research by a group of researchers from the Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) led by professor Robert Ho?yst, the mobility of molecules at length-scales from single to tens of nanometers in the nucleus is presented in detail.

A Molecular superstore

Due to its small size, one might assume that the nucleus has a simple structure and a random molecule distribution. That is by no means the case. The nucleus has an unbelievably complex and fine-tuned layout. The DNA does not resemble a messy tangle of spaghetti; it is efficiently packed into compact structures. Even the nanoscale viscosity of the nucleus determines the mobility of the individual objects inside. To better visualize how well-organized this all is, the nucleus can be described as a superstore. The chromatin fibers work like shelves, holding an assortment of necessary genetic information (i.e., DNA) just like the shop shelves are filled with products. These shelves don't take up the entire space, but rather they are separated within an aisle-like distance that works as a channel. The people crossing the aisles in specific patterns as they shop could be compared to the protein molecules that move somewhat randomly within the nucleus' channels according to the rules of Brownian motion. No matter how crowded the aisle gets, people always find a way to pass by each other, maintaining some distance as they go. The molecules crossing molecular channels do the same without any traffic problems on their way. This allows each molecule to travel efficiently, maintaining the orderliness of a superstore.

Viscosity impact

The molecules that are present in the eukaryotic cells have different sizes. For example, ions are subnanometer in size, protein radii are typically few nanometers; a nucleosome's radius is about 5.5 nm, while folded up chromatin fibers have a radius of about 15 nm. Furthermore, condensed loops of chromatin form higher-level compact structures are boasting a radius of about 150 nm. To understand their mobility within the nucleus, professor Ho?yst's team proposed to place nanometer-sized objects covering the whole spectrum of natural components length-scales found in the nucleus. Polymers, proteins, and nanoparticles having radius from 1.3 to 86 nm in were considered.

To see this intriguing organization at the nanoscale level, specific molecules' mobility was studied using non-invasive techniques such as fluorescence correlation spectroscopy (FCS) and raster image correlation spectroscopy (RICS). Thanks to substances like the GFP (green fluorescent protein) or the rhodamine-based nanoparticles in nanomolar concentration, it was possible to observe the mobility of particular molecules and determine the nucleoplasm viscosity without causing any disruption to cellular activity. These techniques allow scientists to investigate even the most minor changes at the molecular level. The mobility of large nanoparticles was reduced by as much as 6 times compared to the diffusion in an aqueous medium. However, the typical protein-sized molecules diffusion was reduced only 2-3 times. The mobility drastically decreases when the radius of injected objects is larger than 20, more significance on estimations of the diffusion coefficient, it is possible to look closer at the movement and interaction of molecules that happen between particular objects in the nucleus' channels and within the packed structure inside the nucleus. These measurements expand our current understanding of the structure of the nucleus. Having a good understanding of the complexity of the channels within nuclei is crucial as it directly contributes to our knowledge of how large biostructures, perhaps including the medicine of the near future, are transported within the cell.

The first author, dr. Grzegorz Bubak remarks, "Our experiments revealed that eukaryotic cell nucleus is percolated by ?150 nm-wide interchromosomal channels filled with the aqueous diluted protein solution of low viscosity."

The studies quantifying the crowding within cells' nuclei reveal that most molecules can freely pass through this complex structure. Based on experiments supported by theoretical models, it was possible to estimate channels' width (~150 nm) between the chromatin structure. The nuclei channels can constitute as much as 34% of the nuclei's volume which is around 240 fL. If they were narrower, the chromatin fibers would be more dispersed, making the molecules' efficient movement inside impossible. It is fascinating that the nucleus can contain such large amounts of DNA and other chemical elements without disturbing the molecules' migration. This is all thanks to the well-arranged chromatin fibers made by DNA with structural proteins that give the double helix its shape. The mobility of particular chemical elements through the biological fluid in molecular channels is essential in many processes, such as creating specific molecules and forming new protein complex structures.

"These results can be of great importance when designing biological drugs such as therapeutic proteins, enzymes, and monoclonal antibodies, which can have the hydrodynamic radii larger than conventional chemical drugs based on synthetic compounds." - concludes dr. Bubak

As a result of these studies, the mobility of the molecules in the nuclear channels is now described in detail and well-understood for the first time. Thanks to the research presented in this work, we now know how the chromatin fibers govern molecule organization, revealing the intriguing molecular machinery hidden deep inside the nucleus. We are now one step closer to developing therapeutic agents that can be effectively transported into the nucleus.

Credit: 
Institute of Physical Chemistry of the Polish Academy of Sciences

A new dye shakes up solar cells

image: Marko Stojanovic in the Laboratory of Photonics and Interfaces (EPFL) holding a solution of MS5.

Image: 
Jean-David Décoppet and Alejandra Hauser.

In 1991, scientists Brian O'Regan and Michael Grätzel at EPFL published a seminal paper describing a new type of solar cell: the dye-sensitized solar cell (DSSC), also known as "Grätzel cell". Simple and cheap to build while being flexible and versatile, DSSCs are already manufactured on a multi-megawatt scale, cutting a significant slice of the photovoltaic market, which currently supplies almost 3% of all the world's electricity, well in the race to reduce carbon emissions.

Now, Dan Zhang and Marko Stojanovic, two PhD students in Grätzel's lab at EPFL's School of Basic Sciences, have led the development of a simple dye for DSSCs, called MS5. In devices, this new sensitizer can either be used as single dye, and produce an open-circuit voltage - the maximum voltage a solar cell can reach in full sunlight - of 1.24 Volts or as co-sensitizer, along with the commercial dye XY1b, and enable a power conversion efficiency of 13.5 %. Both are among the highest in the field of DSSCs.

The work is published in Nature Communications.

The team used this new dye in combination with another organic sensitizer coded XY1b. Apart from absorbing photons from the blue and yellow domain of the solar emission, the role of the new dye in this tandem is to boost the voltage output of the device by retarding the recombination of charge carriers generated by light. Called MS5, the photosensitizer was used with a copper (II/I) electrolyte to enable the DSSC achieve its impressive efficiency.

"Our work constitutes an important breakthrough in the work of DSSCs and especially dye design," says Michael Grätzel. "It shows that high performances are achievable with a relatively simple dye through judicious molecular engineering of the sensitizer's molecular structure."

Tested under ambient light conditions, the dye showed impressive performance, which is crucial for photovoltaics to be effective under cloudy conditions, or in-door applications to power electronic devices applied e.g. for the internet of things. And last but not least, MS5 is easy to synthesize up to the gram scale using a one-step procedure that researchers describe in their paper.

"Our results not only push the field of dye-sensitized solar cells further, but demonstrate EPFL's leading expertise in the field," says Marko Stojanovic.

Credit: 
Ecole Polytechnique Fédérale de Lausanne

How flashlight fish communicate with light signals in the school

image: Flashlight fish live in schools.

Image: 
RUB, Department of General Zoology and Neurobiology, Stefan Herlitze

Flashlight fish have the ability to generate situation-specific blink patterns resembling a visual Morse code. Researchers at Ruhr-Universität Bochum have shown in laboratory and field experiments that the animals use these light signals to coordinate their behaviour in the school when visibility is limited. Both the light intensity and the blinking frequency affected the animals' behaviour. The team headed by Peter Jägers and Professor Stefan Herlitze from the Department of General Zoology and Neurobiology has shared their findings in the journal Scientific Reports, published online on 19 March 2021. "Our data show that flashlight fish are attracted by the light signals emitted by other school members," points out Jägers.

Milky Way in the water

Flashlight fish of the species Anomalops katoptron have a luminescent organ under their eyes that is filled with luminescent bacteria and which they can occlude so that it looks as if they are blinking. During the day, the animals hide in caves, rock crevices or in dark, deep water. "On moonless nights, up to a thousand individuals migrate in a school into the plankton-rich surface water," says Peter Jägers, who observed the fish in the wild during a diving expedition in the Indo-Pacific. "It is a surreal experience to see the schools - like a Milky Way in the water."

To understand the function of the flashing patterns, the researchers first studied Anomalops katoptron in the lab in a large water tank containing fish dummies that could be digitally controlled to mimic the animals' light signals. They also used infrared cameras to record the movements of individual animals in response to the artificial flashing lights. During the experiments, only one animal was in the tank at a time, with several individuals being tested one after the other.

Flashlight dummies attract fish

When the researchers placed a single dummy that was flashing light in the middle of the tank, the fish moved closer to it the faster the light flashed. In another experiment, 13 lights were positioned around the tank and lit up one after the other at varying time intervals. "We observed a high motivation among the flashlight fish to head towards the light," says Peter Jägers.

Based on the laboratory experiments, the researchers deduced that a faster flashing is a signal for Anomalops katoptron to stay closer to their fellow fish in the school, as the group offers, for example, protection from predators. This theory was confirmed in field experiments. On a diving expedition, the researchers showed that the animals reacted to stress by blinking more rapidly.

Waiting for the school at night in the sea

Diving at night in the dark, the researchers waited until a school of flashlight fish got close. The animals avoided light brighter than moonlight by fleeing immediately. The Bochum team triggered the escape response with dim red light and simultaneously recorded the animals and their blinking patterns with special cameras. This is how they showed that stress was associated with an increased blinking frequency. "We assume that the increased blinking frequency is the signal to follow the other group members more closely under stress," concludes Peter Jägers. "In our study, we demonstrated for the first time that there is a direct link between visually communicated signals under limited light conditions, such as those prevailing at night or in the deep sea, and the school formation of fish. We hope that this can be of help in future studies of, for example, the largely unexplored deep sea."

Credit: 
Ruhr-University Bochum

Health declining in Gen X and Gen Y, national study shows

COLUMBUS, Ohio - Recent generations show a worrying decline in health compared to their parents and grandparents when they were the same age, a new national study reveals.

Researchers found that, compared to previous generations, members of Generation X and Generation Y showed poorer physical health, higher levels of unhealthy behaviors such as alcohol use and smoking, and more depression and anxiety.

The results suggest the likelihood of higher levels of diseases and more deaths in younger generations than we have seen in the past, said Hui Zheng, lead author of the study and professor of sociology at The Ohio State University.

"The worsening health profiles we found in Gen X and Gen Y is alarming," Zheng said.

"If we don't find a way to slow this trend, we are potentially going to see an expansion of morbidity and mortality rates in the United States as these generations get older."

Zheng conducted the study with Paola Echave, a graduate student in sociology at Ohio State. The results were published yesterday (March 18, 2021) in the American Journal of Epidemiology.

The researchers used data from the National Health and Nutrition Examination Survey 1988-2016 (62,833 respondents) and the National Health Interview Survey 1997-2018 (625,221 respondents), both conducted by the National Center for Health Statistics.

To measure physical health, the researchers used eight markers of a condition called metabolic syndrome, a constellation of risk factors for heart disease, stroke, kidney disease and diabetes. Some of the markers include waist circumference, blood pressure, cholesterol level and body mass index (BMI). They also used one marker of chronic inflammation, low urinary albumin, and one additional marker of renal function, creatinine clearance.

The researchers found that the measures of physical health have worsened from the Baby Boomer generation through Gen X (born 1965-80) and Gen Y (born 1981-99). For whites, increases in metabolic syndrome were the main culprit, while increases in chronic inflammation were seen most in Black Americans, particularly men.

"The declining health trends in recent generations is a shocking finding," Zheng said. "It suggests we may have a challenging health prospect in the United State in coming years."

Zheng said it is beyond the scope of the study to comprehensively explain the reasons behind the health decline. But the researchers did check two factors. They found smoking couldn't explain the decline. Obesity could help explain the increase in metabolic syndrome, but not the increases seen in chronic inflammation.

It wasn't just the overall health markers that were concerning for some members of the younger generations, Zheng said.

Results showed that levels of anxiety and depression have increased for each generation of whites from the War Babies generation (born 1943-45) through Gen Y.

While levels of these two mental health indicators did increase for Blacks up through the early Baby Boomers, the rate has been generally flat since then.

Health behaviors also show worrying trends.

The probability of heavy drinking has continuously increased across generations for whites and Black males, especially after late-Gen X (born 1973-80).

For whites and Blacks, the probability of using street drugs peaked at late-Boomers (born 1956-64), decreased afterward, then rose again for late-Gen X. For Hispanics, it has continuously increased since early-Baby Boomers.

Surprisingly, results suggest the probability of having ever smoked has continuously increased across generations for all groups.

How can this be true with other research showing a decline in overall cigarette consumption since the 1970s?

"One possibility is that people in older generations are quitting smoking in larger numbers while younger generations are more likely to start smoking," Zheng said. "But we need further research to see if that is correct."

Zheng said these results may be just an early warning of what is to come.

"People in Gen X and Gen Y are still relatively young, so we may be underestimating their health problems," he said. "When they get older and chronic diseases become more prevalent, we'll have a better view of their health status."

Zheng noted that the United States has already seen recent decreases in life expectancy and increases in disability and morbidity.

"Our results suggest that without effective policy interventions, these disturbing trends won't be temporary, but a battle we'll have to continue to fight."

Credit: 
Ohio State University

Important advance in research on future drugs

image: Madhuranayaki Thulasingam and Jesper Z. Haeggström, researchers at the
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Sweden.

Image: 
Stefan Zimmerman

Most drugs operate via the membranes that surround the body's cells. A study by researchers at Karolinska Institutet in Sweden has now mapped the structure and mechanism of MGST2, a membrane enzyme that, amongst other things, plays a part in chronic inflammation and cancer. The study, which is published in the journal Nature Communications, can make a significant contribution to the development of future drugs.

All our cells are enclosed in a fat-rich membrane. The cells' equivalent to organs, the organelles, are also enclosed by membranes. Embedded in the cell's internal and external membranes are proteins that regulate a large number of vital functions. Almost half of all drugs are effective via membrane proteins, such as enzymes, receptors and transporters.

Researchers at Karolinska Institutet have now, with the aid of X-ray crystallography, molecular dynamics simulations and biochemical techniques, been able to determine the 3D structure and mechanism of an important enzyme embedded in the cell's nuclear membrane.

The membrane enzyme MGST2 (Microsomal Glutathione S-Transferase 2) is the motor of a biochemical process that causes oxidative stress and the formation of oxygen radicals and, subsequently, DNA damage and cell death.

"Membrane proteins are hard to study and it's fantastic that we've managed to determine the crystal structure for MGST2 at high resolution," says the study's first author Madhuranayaki Thulasingam, researcher at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet. "One of the study's findings is that MGST2 is made up of three functional units that are controlled in an unusually sophisticated manner. The three units are involved in mutually coordinated movements, taking turns to perform the enzyme's function one active unit at a time."

MGST2 belongs to a larger family of enzymes that control the formation of prostaglandins and leukotrienes, signal molecules that regulate fever, pain and inflammation of the airways, joints, heart and blood vessels.

The results provide valuable information on the molecular regulation of other members of the enzyme family, many of which are important targets for future drug development.

"We hope that our results will be able to contribute to the development of drugs for many diseases characterised by increased synthesis of oxygen radicals and cell death, such as chronic inflammation, cancer and side-effects of radio- and chemotherapy," says principal investigator Jesper Z. Haeggström, professor at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet.

Credit: 
Karolinska Institutet

Parkinson's disease: When molecular guardians need to be protected

image: Fluorescence microscopy image of tinted mitochondria

Image: 
Nicola Roverato, University of Konstanz

Parkinson's disease is the second most common, age-related, neurodegenerative disease: In Germany alone, about 300,000 people are affected and experience sometimes major limitations to their quality of life. Although Parkinson's is so widespread, there is still no treatment that targets the cause of the disease and can stop it in its tracks.
However, current research provides new hope: A research team at the University of Konstanz led by Professor Marcus Groettrup describes a new approach for developing future treatments for Parkinson's. The biologists demonstrated that the ubiquitin-like protein FAT10 inhibits the molecular defence mechanisms protecting the brain from Parkinson's disease. The biological mechanism is tricky: FAT10 causes processes in our own body that degrade the body's molecular "guardians" against Parkinson's disease (the enzyme Parkin). Instead of getting rid of damaged mitochondria in brain cells, Parkin is itself disposed of by the body. The research results were published in the scientific journal Cell Reports on 16 March 2021.

Damaged power plants of the cells

Parkinson's disease develops as a result of nerve cells dying off in the mesencephalon (midbrain). This is caused by faulty disposal of damaged mitochondria, the cells' "power plants". When damaged mitochondria are not disposed of by the body, oxygen radicals develop in the brain. These, in turn, damage the nerve cells, causing them to die.

So that the body can dispose of mitochondria, they have to be marked by a signalling substance. This can be compared with labelling them as "broken - please throw away". The enzyme Parkin is responsible for labelling damaged mitochondria. The molecular label it gives them contains the protein ubiquitin.

Wrongly labelled

This is where the protein FAT10 comes into play. FAT10 has a very similar structure and function to ubiquitin. It is also a signalling substance that labels other molecules for disposal. Unfortunately, FAT10 is the wrong label for mitochondria. FAT10 not only labels the damaged mitochondria, but also the enzyme Parkin for the body to dispose of.

To use a picture: It would be like labelling the cell's own guardians for disposal - the very ones that otherwise label damaged mitochondria for disposal. The body then does what the labels tell it to do. The more guardians are disposed of, the fewer damaged mitochondria can be correctly labelled for disposal. What happens as a result? The body's defence processes do not dispose of the damaged mitochondria - and the brain cells themselves are damaged over time.

"We hope this discovery provides a new approach to developing an effective treatment for Parkinson's. An inhibitor for FAT10 could possibly be used to limit the disposal of Parkin and ensure that damaged mitochondria are disposed of correctly", says Marcus Groettrup.

Credit: 
University of Konstanz